Clinical Trial: NCT05872854
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Ellen Kim, MD |
| Information Provided By: | Abramson Cancer Center at Penn Medicine |
| Last Update Posted: | 2026-02-09 |
Study Overview
Brief Summary
The goal of this clinical trial is to assess the benefit of continuous treatment with synthetic hypericin ointment (HyBryte) and visible light in patients with mycosis fungoides for up to 12 months (54 weeks). Funding Source: FDA OOPD.
Official Title
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light
Conditions
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Intervention / Treatment
- Drug: Hypericin
- Other: Visible Light
Other Study ID Numbers
- 05622 (UPCC)
- RW-HPN-MF-01
- 851617
Start Date (Actual)
2023-08-21
Primary Completion Date (Actual)
2025-12-22
Study Completion Date (Actual)
2025-12-22
Enrollment (Actual)
10
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Ellen Kim, MD |
| Information Provided By: | Abramson Cancer Center at Penn Medicine |
| Last Update Posted: | 2026-02-09 |
Study Overview
Brief Summary
The goal of this clinical trial is to assess the benefit of continuous treatment with synthetic hypericin ointment (HyBryte) and visible light in patients with mycosis fungoides for up to 12 months (54 weeks). Funding Source: FDA OOPD.
Official Title
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light
Conditions
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Intervention / Treatment
- Drug: Hypericin
- Other: Visible Light
Other Study ID Numbers
- 05622 (UPCC)
- RW-HPN-MF-01
- 851617
Start Date (Actual)
2023-08-21
Primary Completion Date (Actual)
2025-12-22
Study Completion Date (Actual)
2025-12-22
Enrollment (Actual)
10
Study Type
Interventional
Phase
Phase 2